Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOBIKY)

Drug Name
Bexarotene Drug Info
Synonyms
Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
82146
ChEBI ID
CHEMBL1023
CAS Number
CAS 153559-49-0
TTD Drug ID
D0N0RU
INTEDE Drug ID
DR0208
ACDINA Drug ID
D00068

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Retrograde endocannabinoid signaling -1.64 4.51e-2 118/148 (79.73%) CACNA1S;GRM5;NDUFB1;...
GABAergic synapse -1.65 4.38e-2 76/89 (85.39%) ADCY8;SLC6A13;GNAO1;...
Insulin secretion -1.67 4.11e-2 75/86 (87.21%) CACNA1S;CACNA1D;PRKACA;...
Adherens junction -1.67 4.09e-2 63/71 (88.73%) AFDN;MAP3K7;YES1;...
Glutamatergic synapse -1.68 4.15e-2 97/114 (85.09%) PLA2G4A;GRM5;CACNA1D;...
Rap1 signaling pathway -1.68 3.98e-2 184/210 (87.62%) FGF7;CRKL;RHOA;...
Gastric cancer -1.69 4.04e-2 122/149 (81.88%) TP53;FGF7;CTNNA2;...
Oxytocin signaling pathway -1.70 4.01e-2 128/154 (83.12%) RHOA;ROCK2;CACNB4;...
Mitophagy -1.74 3.06e-2 56/68 (82.35%) TFEB;TAX1BP1;BNIP3;...
Long-term depression -1.74 3.06e-2 55/60 (91.67%) GNA11;MAPK1;GNAQ;...
Phenylalanine metabolism -1.75 3.28e-2 14/17 (82.35%) MAOA;HPD;ALDH3A1;...
Adrenergic signaling in cardiomyocytes -1.75 3.53e-2 130/150 (86.67%) AKT1;PPP2R5D;CACNB4;...
Pentose phosphate pathway -1.76 3.58e-2 25/30 (83.33%) PGD;RPIA;TKT;...
Salivary secretion -1.76 3.77e-2 76/93 (81.72%) ATP2B2;KCNMA1;ADCY8;...
Circadian entrainment -1.76 4.15e-2 85/97 (87.63%) MAPK3;NOS1AP;GRIA3;...
Nitrogen metabolism -1.80 3.13e-2 16/17 (94.12%) CA4;CPS1;CA12;...
Amphetamine addiction -1.82 2.41e-2 57/69 (82.61%) PPP1CB;PRKCA;MAOA;...
Vibrio cholerae infection -1.83 2.54e-2 44/50 (88%) PRKACB;ATP6V1F;ATP6V1B2;...
Dopaminergic synapse -1.85 2.72e-2 115/132 (87.12%) GRIA3;KIF5C;PPP2R3A;...
Gastric acid secretion -1.90 8.89e-3 63/76 (82.89%) KCNJ2;ADCY8;KCNQ1;...
Porphyrin and chlorophyll metabolism -1.93 3.71e-3 23/43 (53.49%) HCCS;ALAD;CPOX;...
Primary bile acid biosynthesis -2.01 0.00e+0 15/17 (88.24%) AKR1D1;SCP2;CYP46A1;...
Bile secretion -2.02 0.00e+0 68/90 (75.56%) SLC22A7;SLC22A8;HMGCR;...
Synaptic vesicle cycle -2.15 0.00e+0 63/78 (80.77%) SLC17A7;SLC1A1;ATP6V1F;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H